Dr Patrick E. Sewell

Founder and Chief Science Officer, Triple Helix Science

Gene and cell therapy delivery, from the laboratory to the patient

Roughly monthly. Unsubscribe any time.

Contact for media →

Featured inScience 2.0Wellness CuratedSober Head PodcastCancer Center for HealingOC Talk RadioThe Journal of UrologyAmerican Journal of RoentgenologyRadioGraphics

What Patrick writes about

Dr Patrick E. Sewell writes about shifting medicine from lifelong treatment to early prevention and cure, and the gene and cell therapies that make it possible. He covers the economics keeping proven cures from patients, why emerging nations can build preventative healthcare from day one, and what decades as an interventional oncologist and radiologist taught him about catching disease early.

Patrick's newsletter, The Third Strand, comes out roughly monthly, on the therapies ready to replace lifelong drug regimens, and what's standing in their way. The latest issue is "The economics of preventive precision medicine".

Holds US patent 12,564,646 (2026) on intranasal AAV delivery of hTERT and Klotho. Author of eight books and more than 80 peer-reviewed papers.

Newsletters

The Third StrandPatrick's newsletter

Comes out roughly monthly, on the therapies ready to replace lifelong drug regimens, and what's standing in their way.

Free. Unsubscribe any time.

Latest issue

The economics of preventive precision medicine

Predictive precision medicine means we can identify and intervene before potential problems develop, but the global healthcare model needs to catch-up first.

22 Oct 2026 · 4 min read

Selected coverage

21 Sept 2026The Guardian Paradox: Our Biology Prevents Cancer But Increases AgingScience 2.0, interview
8 Jul 2026Gene Therapy Explained: How It Could Transform Your HealthWellness Curated, broadcast
11 Sept 2025A New Era Against Cancer, Dementia, and Aging With GenesSober Head Podcast, broadcast
28 Feb 2025Perfectly Healthy: The Future of Cancer Treatment is Here TodayCancer Center for Healing, broadcast
9 Jan 2024Dr. Patrick Sewell on Minimally Invasive Image Guided SurgeryOC Talk Radio, interview

Media reaction

Democratising gene and cell therapy

"Gene and cell therapies are no longer a luxury for the elite. The economies of scale are here, and they're here now. These therapies have real use cases, from the most complex cancers to Alzheimer's and neurodegeneration, and they could transform healthcare systems worldwide. For the first time, preventative healthcare can be democratised on a global scale."
Dr Patrick E. SewellDr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026
1 of 2

Areas of expertise

All areas →
Gene TherapyInterventional OncologyNeurodegenerationPrecision MedicineRegenerative MedicineLongevityMetabolic HealthMuscle Biology

Most asked

Who is Dr. Patrick E. Sewell?
Dr. Patrick E. Sewell is Founder and Chief Science Officer at Triple Helix Science, working on gene and cell therapy delivery, from the laboratory to the patient. Sewell's subjects are gene therapy, interventional oncology, longevity, neurodegeneration, precision medicine, regenerative medicine, metabolic health and muscle biology. The question Sewell returns to in writing and in comment is how a therapy physically reaches its target tissue, and how these innovations can be used to combat the most complex medical conditions.
What will Patrick Sewell comment on for press, and how fast does he reply?
Dr. Patrick E. Sewell comments on gene and cell therapy delivery: vector choice, route of administration, dosing, biodistribution, and what a delivery method does to trial design, across gene therapy, interventional oncology, neurodegeneration, regenerative medicine and muscle biology. Sewell does not discuss individual patients or a named company's unpublished data. Press requests run through Triple Helix Science, which confirms against the stated deadline whether Sewell can speak rather than leaving the request open.
What does Patrick Sewell think gene therapy companies get wrong?
Delivery gets settled last, and Dr. Patrick E. Sewell argues it should be settled first. Sewell's position is that most gene therapy programmes lock the construct and then go looking for a route to the target tissue, which turns the route into a constraint instead of a design choice. A construct that works in a dish and reaches too few cells in a patient has failed on delivery, not on biology.
Why does Patrick Sewell argue that regional delivery deserves more attention than it gets?
Regional delivery changes the dose that actually matters, and Dr. Patrick E. Sewell argues the field still files it under logistics. Sewell's view is that image-guided and catheter-based delivery into a target organ or limb is a dose-determining variable, because the number that counts is how much reaches the tissue rather than how much is infused. That argument carries across interventional oncology, muscle biology and neurodegeneration alike.

Contact for media

Reach Patrick directly for comment, background or an interview, on deadline or ahead of one.

Straight to the Triple Helix Science press team.